Navigation Links
VIA Pharmaceuticals Featured at American Heart Association Scientific Sessions 2009
Date:11/4/2009

al results to differ materially from current expectations include, but are not limited to:

  • our ability to comply with the NASDAQ rules for continued listing in order to maintain the listing of our common stock on NASDAQ;
  • our ability to obtain necessary financing in the near term, including amounts necessary to repay the loan from Bay City Capital by the December 31, 2009 maturity date (or earlier if certain repayment acceleration provisions are triggered);
  • our ability to control our operating expenses;
  • our ability to comply with covenants included in the loan from Bay City Capital;
  • our ability to timely recruit and enroll patients in any future clinical trials;
  • our failure to obtain sufficient data from enrolled patients that can be used to evaluate VIA-2291, thereby impairing the validity or statistical significance of our clinical trials;
  • our ability to successfully complete our clinical trials of VIA-2291 on expected timetables and the outcomes of such clinical trials;
  • complexities in designing and implementing cardiometabolic clinical trials using surrogate endpoints in Phase 1 and Phase 2 clinical trials which may differ from the ultimate endpoints required for registration of a candidate drug;
  • the results of our clinical trials, including without limitation, with respect to the safety and efficacy of VIA-2291;
  • if the results of the ACS and CEA studies, upon further review and analysis, are revised, interpreted differently by regulatory authorities or negated by later stage clinical trials;
  • our ability to obtain necessary FDA approvals, including to initiate future clinical trials of VIA-2291;
  • our ability to successfully commercialize VIA-2291;
  • our ability to identify potential clinical candidates from the family of DGAT1 compounds licensed and move them into preclinical development;
  • our ability to obtain and protect our intellectual prope
    '/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Reportlinker Adds Gastrointestinal Pharmaceuticals: Technologies and Markets
2. Peregrine Pharmaceuticals Regains Full Compliance With Nasdaq Continued Listing Requirements
3. Isis Pharmaceuticals to Present at the 2009 Canaccord Adams Cardiovascular Conference
4. Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDAs BYETTA(R) (Exenatide) Injection Update
5. Quark Pharmaceuticals to Present Data on its siRNA Therapeutic Programs in Kidney and Lung Diseases
6. Warner Chilcott Completes Acquisition of P&Gs Global Branded Prescription Pharmaceuticals Business
7. NeoStem Acquires China Biopharmaceuticals Holdings, Inc.; Obtains Controlling Interest in Profitable Leading Chinese Pharmaceutical Company
8. Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
9. China Biopharmaceuticals Holdings, Inc. Shareholders Overwhelmingly Support Merger with NeoStem, Inc., a NYSE AMEX Listed Company Trading Under Symbol NBS
10. Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full-Year Financial Guidance
11. Dr. Harry Kovelman Joins Ferring Pharmaceuticals as Associate Medical Director for Orthopaedics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... 14, 2014  GenSpera, Inc. (OTCQB: GNSZ), a ... of cancer, announces that Kareg Corporation,s Director of ... the following research report on  the company. ... of Research, Kareg Corporation, Initiating Coverage with a ... full report: http://www.genspera.com/press/140711_Genspera_research_report_July2014.pdf GNSZ ...
(Date:7/14/2014)... 2014  Otonomy, Inc., a clinical-stage biopharmaceutical company focused ... diseases and disorders of the inner and middle ear, ... statement on Form S-1 with the U.S. Securities and ... offering of shares of its common stock. All shares ... will be offered by Otonomy. The number of shares ...
(Date:7/14/2014)... and LONDON , July 14, 2014 ... IXICO plc (AIM: IXI) jointly announced today the formation ... companies. Dr. Edward Ashton , Ph.D., chief scientific ... have seven members. "The formation of this ... the international commercial and operational alliance we signed with ...
Breaking Medicine Technology:Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 2Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 3Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 4Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 5Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 6Otonomy Files Registration Statement for Proposed Initial Public Offering 2VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 2VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 3VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 4VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 5VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 6VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 7VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 8VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 9
... YORK, Sept. 21 An eminent international panel of ... LLY ) to receive a World Business and ... successful partnerships in the battle against multidrug-resistant tuberculosis (MDR-TB). ... of The Lilly MDR-TB Partnership demonstrate a clear linkage ...
... According to Millennium Research Group (MRG), the global authority ... new growth factors, combined with greater variety and improved features ... market to nearly $2.3 billion through 2015. Medtronic ... AMPLIFY , is set to be released in the US ...
Cached Medicine Technology:Lilly Recognized with World Business and Development Award for Tuberculosis Initiative 2Lilly Recognized with World Business and Development Award for Tuberculosis Initiative 3Introduction of New Products and Increased Uptake of Innovative Materials to Drive US Bone Graft Substitute Market to Nearly $2.3 Billion by 2015 2Introduction of New Products and Increased Uptake of Innovative Materials to Drive US Bone Graft Substitute Market to Nearly $2.3 Billion by 2015 3
(Date:7/14/2014)... 14, 2014 Physical fitness may buffer some of the ... a new study by researchers from the American Cancer ... The study appears in the journal Mayo Clinic ... time and obesity and blood markers associated with cardiovascular ... account. , Sedentary behavior has been linked to an ...
(Date:7/14/2014)... Wisconsin (PRWEB) July 14, 2014 Secure ... software security, is partnering with the Software Assurance Marketplace ... to improve the software that drives everyday life. , ... institutions and housed in the Morgridge Institute for Research, ... S&T to advance software security practices by building a ...
(Date:7/14/2014)... 13, 2014 (HealthDay News) -- Eye tests could be ... Alzheimer,s disease, two new studies suggest. In one ... certain eye test found a significant association between levels ... and levels of the plaques in the brain. Beta-amyloid ... This type of eye test could be used ...
(Date:7/14/2014)... Doheny HealthDay Reporter MONDAY, ... be linked to multiple health issues, but dementia isn,t one ... seniors, widowhood may even delay dementia, the researchers found. ... spouse was associated with a later age of developing full-blown ... Dr. Bryan Woodruff. Woodruff, an assistant professor of ...
(Date:7/14/2014)... July 14, 2014 KeyPoint Credit Union ... 6th Annual 5K run and one-mile family fun walk. ... the park attractions, and finishes inside Levi’s® Stadium. , ... over $150,000 for the Mission City Community Fund. All ... County. , Seasoned athletes, part-time pavement-pounders and walkers ...
Breaking Medicine News(10 mins):Health News:Physical fitness associated with less pronounced effect of sedentary behavior 2Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 2Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 3Health News:Eye Tests Might Help ID Alzheimer's, Studies Suggest 2Health News:Widowhood May Delay Dementia in Some Seniors, Study Finds 2Health News:Widowhood May Delay Dementia in Some Seniors, Study Finds 3
... Allerca, Inc., is now taking orders for its Allerca ... is a boon to the several allergy sufferers who ... that they searched for natural variations in the cat ... trait through breeding. Hence these animals were not transgenic,in other ...
... Hopkins Bloomberg School of Public Health has discovered that ... pathogens and plasmodium parasites. The study narrowed down on ... immune system of mosquitoes. ,All of the ... the malaria parasites were also important for the resistance ...
... are diseases which occur due to progressive degeneration of ... and fatal diseases are Huntington's, ALS and Kennedy disease. ... for such diseases are the blockage of the transport ... the mechanism underlying the cell transport is unraveled then ...
... sexual terms more than women. Men rate themselves higher ... //reported in the latest issue of Psychology of Women ... as indicating sexual interest after a short conversation – ... partners introduced themselves and talked about college experiences. There ...
... of the Holocaust are more likely to suffer from cancer ... Raviv and his colleagues at Israel's //Haifa University suspect that ... Jews during World War II. ,The researchers looked ... four million Israelis of European origin - comparing those who ...
... her grandmother gave Isabelle Taylor, of St Annes, Lancs, a ... her grand child would end up constantly // sending text ... known as ‘repetitive strain injury’ and becoming the youngest ... ,Her mother, Jane, explains that she's constantly on the phone ...
Cached Medicine News:Health News:What Ticks the Mosquito immune system? 2Health News:Transport of Proteins Unravels the Mystery behind Neurodegenerative Diseases 2
... Our breadth of infectious disease ELISA products ... With standard assay protocols for faster integration ... ELISA products provide increased reliability and run-to-run ... antibody detection assays for a wide range ...
... infectious disease ELISA products make us a ... protocols for faster integration into the busy ... increased reliability and run-to-run consistency. Our Infectious ... for a wide range of serological assays ...
... disease ELISA products make us a leader ... for faster integration into the busy laboratory, ... reliability and run-to-run consistency. Our Infectious Disease ... a wide range of serological assays including ...
... We offer a complete line ... laboratorians state-of-the-art monoclonal and monoclonal/polyclonal ... detection of enteric pathogens in ... products for Clostridium difficile, Entamoeba ...
Medicine Products: